Literature DB >> 8996479

Outcome of aneurysmal subarachnoid hemorrhage in patients on anticoagulant treatment.

G J Rinkel1, N E Prins, A Algra.   

Abstract

BACKGROUND AND
PURPOSE: Intracranial hemorrhage is an important complication of treatment with anticoagulants. We studied outcome of aneurysmal subarachnoid hemorrhage (SAH) occurring in patients on anticoagulant drugs because this may influence management of patients needing anticoagulant treatment but with increased risk of aneurysmal hemorrhage.
METHODS: From the prospective database of patients admitted with SAH to the Utrecht University Hospital, we compared 3-month outcome in patients with or without anticoagulant drugs by means of stratified analyses to adjust relative risks for biological and clinical differences between the two groups.
RESULTS: Death or dependency after SAH occurred in 14 of 15 patients on anticoagulant treatment and in 62 of 126 patients not being treated with anticoagulants (relative risk, 1.9; 95% confidence interval, 1.5 to 2.4). The patients on treatment with anticoagulants were more often comatose on admission; the frequencies of rebleeding, secondary ischemia, and hydrocephalus were not higher in patients on anticoagulants. In the stratified analysis the worse outcome in the group on anticoagulant drugs was not essentially influenced by differences in sex, age, cardiovascular history, site of aneurysm, amount of cisternal blood, or extension of hemorrhage into the ventricles.
CONCLUSIONS: The outcome of aneurysmal SAH in patients or anticoagulant drugs is extremely poor. The explanation for the worse prognosis in patients on anticoagulants lies in a worse clinical condition from the outset. The poor outcome urges a reconsideration of the balance of risks for anticoagulant treatment in patients with an unoperated intracranial aneurysm or with a family history of SAH and may lead to withholding treatment with anticoagulant drugs or to a preventive operation.

Entities:  

Mesh:

Year:  1997        PMID: 8996479     DOI: 10.1161/01.str.28.1.6

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

Review 1.  Should patients with autosomal dominant polycystic kidney disease be screened for cerebral aneurysms?

Authors:  M N Rozenfeld; S A Ansari; A Shaibani; E J Russell; P Mohan; M C Hurley
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-04       Impact factor: 3.825

2.  The notion of "warning leaks" in subarachnoid haemorrhage: are such patients in fact admitted with a rebleed?

Authors:  F H Linn; G J Rinkel; A Algra; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

3.  Outcome Following Hemorrhage From Cranial Dural Arteriovenous Fistulae: Analysis of the Multicenter International CONDOR Registry.

Authors:  Matthew J Koch; Christopher J Stapleton; Ridhima Guniganti; Giuseppe Lanzino; Jason Sheehan; Ali Alaraj; Diederik Bulters; Louis Kim; W Christopher Fox; Bradley A Gross; Minako Hayakawa; J Marc C van DijK; Robert M Starke; Junichiro Satomi; Adam J Polifka; Gregory J Zipfel; Sepideh Amin-Hanjani
Journal:  Stroke       Date:  2021-08-26       Impact factor: 10.170

Review 4.  Management of Unruptured Intracranial Aneurysms.

Authors:  Deena M Nasr; Robert D Brown
Journal:  Curr Cardiol Rep       Date:  2016-09       Impact factor: 2.931

5.  Need for Continued Use of Anticoagulants After Intracerebral Hemorrhage.

Authors:  Conrado J. Estol; Carlos S. Kase
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-07

6.  Management of unruptured intracranial aneurysms.

Authors:  Lindsy N Williams; Robert D Brown
Journal:  Neurol Clin Pract       Date:  2013-04

7.  Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy.

Authors:  H Bart van der Worp; Susanne Fonville; Lino M P Ramos; Gabriël J E Rinkel
Journal:  Neurocrit Care       Date:  2008-10-30       Impact factor: 3.210

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.